Teva recently released the following press release looking at the effectiveness and patient satisfaction for HD chorea with the 4 week titration kit for AUSTEDO®.

Quick Notes

• Titration of a medicine means slowly increasing the dose of a medicine by very small amounts over days, weeks, or even months, to find the right dose that is effective for you

• Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results

• START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO

• AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for this progressive condition1,2

Read the Full Press Release